MediLink reported phase 3 results for a Roche-partnered B7-H3-directed antibody-drug conjugate in small-cell lung cancer, with the study hitting its primary endpoint but trailing a competitor benchmark. The ADC’s median overall survival missed the bar set by GSK’s rival asset in cross-trial survival comparisons. For oncology stakeholders, the update underscores how tightly efficacy metrics are being scrutinized across the same clinical space, even when studies are not head-to-head. It also signals continued intensity around B7-H3 as a target for ADC-based strategies in relapsed or refractory small-cell disease. Separately, an antibody-drug conjugate strategy in EGFR-mutated lung cancer reached a recommended phase 3 dose, adding another late-stage datapoint for ADC dosing escalation. Together, the readouts show that ADC development continues to mature on both target validation and regimen optimization. Still, the MediLink/Roche outcome adds pressure for differentiators beyond single endpoints, since survival is increasingly used as the headline yardstick by investors and trial designers.